FDA decision: Oveporexton by Takeda (this year)
As of Tue, 04 Aug 2026 19:09:41 UTC, Kalshi traders price Yes (98.0%). The market has $2K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 98.0% | 98.0¢ | 2.0¢ |
Market details
- Venue: Kalshi
- Volume: $2K
- Liquidity: $2K
- Closes:
Sources
Related markets
- Who will be the next CEO of NVIDIA?
- S&P close price end of 2026?
- Nasdaq-100 close price end of 2026?
- Which brands will advertise during the World Soccer Cup Final
- Will GameStop acquire eBay this year?
- When will Apple release the iPhone 18?
More markets like this
- FDA decision: Saroglitazar by Zydus Therapeutics (this year)
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)
- FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Fed decision in December?
- Fed decisions (Oct-Jan)
- Fed decisions (Sep–Dec)
- Fed decisions December 2026 to March 2027?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.